|
Mon, 05/03/2021 - 06:47 |
Top news stories from AMA Morning Rounds: Week of May 3, 2021 |
AMA |
|
Wed, 01/08/2020 - 21:11 |
Blueprint Medicines Announces FDA Approval of AYVAKIT (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor |
Blueprint Medicines |
|
Tue, 03/05/2019 - 08:40 |
SPRAVATO uses the first new mechanism of action in decades to treat major depressive disorder 1,2,3 |
Johnson and Johnson |
|
Wed, 01/30/2019 - 03:32 |
SUPPLEMENTARY NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR FYCOMPA AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES, AS WELL AS NEW FORMULATION |
EISAI |
|
Fri, 12/21/2018 - 16:11 |
Acorda Therapeutics Announces FDA Approval of INBRIJA (levodopa inhalation powder) |
Acorda |
|
Thu, 12/20/2018 - 03:42 |
LYNPARZA (olaparib) Meets Primary Endpoint in Phase 3 SOLO-3 Trial for the Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer |
Cubist Pharmace... |
|
Wed, 12/19/2018 - 04:35 |
LYNPARZA (olaparib) Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer |
Cubist Pharmace... |
|
Sun, 12/16/2018 - 23:00 |
Patient-centered Care is the Focus and Priority of the 2019 Standards of Medical Care in Diabetes, Published Today by the American Diabetes Association |
American Diabet... |
|
Wed, 12/12/2018 - 10:47 |
Havana Embassy Phenomenon: Researchers Report Acute Findings |
UniversityofPit... |
|
Mon, 12/10/2018 - 07:06 |
Astellas Launches XOSPATA (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation |
Astellas |
|
Fri, 12/07/2018 - 02:26 |
Opioid Prescriptions Can Be Drastically Reduced After Surgery with No Increase in Pain, Study Shows |
Roswell Park Ca... |
|
Wed, 12/05/2018 - 21:55 |
FDA Approves Genentechs Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer |
Genentech |
|
Tue, 12/04/2018 - 23:19 |
Genentechs Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment |
Genentech |
|
Mon, 12/03/2018 - 20:55 |
FDA Grants Priority Review to Genentechs Tecentriq in Combination With Chemotherapy for the Initial Treatment of Extensive-Stage Small Cell Lung Cancer |
Genentech |
|
Mon, 12/03/2018 - 06:01 |
Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) |
Astellas |
|
Sun, 12/02/2018 - 23:09 |
New Venclexta Data Demonstrate Deep Responses in Two of the Most Common Types of Leukemia |
Genentech |
|
Sun, 12/02/2018 - 10:54 |
Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID In Combination with Rituximab (R) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018 |
BMS |
|
Sat, 12/01/2018 - 23:31 |
Real-world data show Novartis drug Revolade improves outcomes for ITP patients compared to other second-line therapies |
Novartis |
|
Sat, 12/01/2018 - 05:02 |
Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma |
Regeneron |
|
Sat, 12/01/2018 - 01:20 |
Novartis announces longer-term analyses from pivotal Kymriah trials that showed durable responses are maintained in patients with advanced blood cancers |
Novartis |
|
Wed, 11/28/2018 - 17:56 |
Approvals Based on Findings from the Pivotal Phase 3 DRIVE-AHEAD and DRIVE-FORWARD Trials Evaluating the Efficacy and Safety of DELSTRIGO and PIFELTRO Through 96 Weeks |
Merck |
|
Wed, 11/28/2018 - 05:50 |
XOSPATA (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation |
Astellas |
|
Tue, 11/27/2018 - 12:13 |
Tevas Generic Version of EpiPen (Epinephrine Injection, USP) Auto-Injector 0.3 mg Now Available in Limited Quantity in the United States |
Teva Pharmaceutical |
|
Tue, 11/27/2018 - 07:08 |
Tevas Generic Epinephrine Injection Now Available in Limited Quantity in the US |
Teva Pharmaceutical |
|
Mon, 11/26/2018 - 20:32 |
Pfizer Receives Six Months Pediatric Exclusivity for LYRICA (pregabalin) |
Pfizer |
